Teva and Servier plan Hungarian expansions
Plans to expand operations in Hungary have come from both the Israeli generics giant Teva Pharmaceutical Industries and the French independent drugmaker Laboratoires Servier.
Teva is to extend its production capacity with an investment of $100.0 million at its Debrecen site and is reportedly viewing other potential sites in Ireland, Poland and the Czech Republic. The company will apply to the Hungarian investment body, the ITDH, to obtain government support for its project.
Currently, the Israeli group produces drugs in the former Biogal unit at Debrecen, as well as in Goedoello, its previous vaccine production facility and at a site in the north east of the country. The company's sales in Hungary last year fell slightly - declining 1.5 billion forint ($8.5 million) to 32.5 billion forint. However, this is in line with other drugmakers' experiences due to Hungarian government moves (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze